Growth axis
Tesamorelin
Used for visceral fat, the GH/IGF-1 axis and body composition (GHRH analogue).
What it is used for
- Visceral adipose tissue (indications / research)
- GH → IGF-1 axis
- Body composition (community discussion)
- Lipid metabolism in studied populations
Disclaimer — Research Use Only
Materials listed on this website are supplied for laboratory research only (Research Use Only). They are not intended for human consumption.
Quick Facts
- Category
- Growth axis
- Research status
- Approved in selected indications (outside MarcinLabs)
- Strength (illustration)
- 10 mg
- Price-list variants
- 5mg · 10mg · 20mg
- Also known as
- —
Overview
Tesamorelin is a synthetic GHRH analogue. Literature discusses it in contexts such as HIV-associated lipodystrophy and GH/IGF-1 axis markers — always within defined indications and clinical supervision.
What it is used for
Community and research context — not a medical indication or treatment advice.
- Visceral adipose tissue (indications / research)
- GH → IGF-1 axis
- Body composition (community discussion)
- Lipid metabolism in studied populations
Tesamorelin is a GHRH analogue — in medicine linked among other things to visceral-fat reduction in specific indications (country-dependent). In research / fitness communities it is discussed more broadly: body composition, “recomp”, growth axis. It is not an anabolic steroid; keep the narrative on GH/IGF-1 and visceral fat, without bodybuilding promises.
For people reading about the growth axis and visceral fat — not for “quick mass” from forums.
How it works
It stimulates endogenous growth-hormone release via the GHRH receptor. Higher GH may raise IGF-1 and influence lipid metabolism. Effect depends on dose, duration, sleep, metabolic status and whether a clinical indication exists at all.
It stimulates pituitary growth-hormone release via the GHRH receptor, secondarily affecting IGF-1 and metabolic processes studied in clinical protocols.
How it is used (research context)
From protocols and documentation — not a dosing guide.
In registered contexts: subcutaneous injections per the label. In research: reconstitution + SC use appears in documentation — without a universal “cut protocol”. Medical-side IGF-1 / safety assessment is needed.
Key takeaways
- Different use-case than GLP-1 (not primarily “anti-appetite”)
- Monitoring the GH/IGF-1 axis makes clinical sense
- Risks: oedema, glucose effects, cost, source quality
- Do not confuse with CJC/ipa — related pathways, different molecules
Who this content is for: For people reading about the growth axis and visceral fat — not for “quick mass” from forums.
Current research
Approved in selected indications (outside MarcinLabs)
In some countries it has approved indications. Outside those indications, use remains a clinical and legal matter beyond MarcinLabs.
Contexts from literature — not therapeutic indications.
- Visceral adipose tissue (selected populations)
- GH/IGF-1 axis
- Body composition
- Long-term safety in labelled indications
Potential side effects
- Oedema, joint pain, injection-site reactions (reported in studies)
- Effects on glucose and IGF-1 need clinical monitoring
- Oncology and endocrine contraindications — clinician assessment
Frequently asked questions
Is tesamorelin a “gym peptide”?
Related scientific papers
Related YouTube videos
YouTube HubNo matching videos — see the YouTube Hub.
Related MarcinLabs articles
ResearchNo direct notes — see the Research Hub.
Related peptides
In the research library
Tesamorelin